Amend the paragraph beginning on page 14, line 20 to recite as follows:

Thus, as set forth above, in one embodiment, the core sequence from N-terminal to C-terminal is Asn-Ser-Asn-Gln-Ile (NSNQI) (SEQ ID NO:1) and in a second embodiment the core sequence is Ser-Asn-Gln (SNQ). Each amino acid in the core sequences is an L-amino acid. Alternatively, a cyclic synthetic peptide of the present invention can have a "core" sequence which is the reverse of one of the above-noted core sequences, i.e., from N-terminal to C-terminal, IQNSN (SEQ ID NO:41) and QNS. When the core sequence is reversed, each amino acid of the core sequence is a D-amino acid.

Amend the paragraph beginning on page 25, line 23 to recite as follows:

Example 1. Synthesis and Characterization of a C-C' loop Cyclic Heptapeptide: CNSNQIC (SEQ ID NO:45)

The peptide CNSNQIC (SEQ ID NO:45) was synthesized using conventional methods of peptide synthesis. Peptides were synthesized on an Applied Biosystem (Foster City, CA) 430A fully automated peptide synthesizer according to methods of Jameson et al., 1988, Science 240:1335. The peptides containing internal cysteine residues were refolded and oxidized by dissolving them at 100 μg/ml in 0.1 M NH_4HCO_3 and stirring overnight exposed to air at 23°C. The peptides show greater than 95% intramolecular disulfide bonding at the end of this procedure as monitored by Ellmans reagents, HPLC analysis and gel filtration. Peptides were lyophilized, resuspended in complete medium and filtered through a 0.22 μ filter prior to use in biological assays.

Amend the paragraph beginning on page 26, line 19 to recite as follows:

Example 2. Synthesis of the peptide: YCNSNQIC (SEQ ID NO:53)

The peptide YCNSNQIC (SEQ ID NO:53) was synthesized and tested *in vitro* in human and murine MLR assay and, *in vivo*, in an EAE protocol. The peptide was found to have inhibitory activity comparable to the cyclic peptide CNSNQIC (SEQ ID NO:45).

REMARKS

The specification has been amended to incorporate the sequence identifiers of the recited amino acid sequences, in accordance with 37 C.F.R. § 1.821 *et seq.* No new matter is introduced by these amendments.

In the Communication mailed July 29, 2002, the Examiner alleges that "[s]equences without SEQ ID NO: tags are disclosed on pages 5, 14, 19, 20, 25 and 26." In